ClinicalTrials.gg
Not yet recruitingNCT07828470Updated Sep 18, 2026

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of KL0011034 Injection Administered by Continuous Infusion in Healthy Adult Subjects

A Phase 1 interventional study of KL0011034 injection and propofol injectable emulsion in Healthy Volunteers, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, propofol position-controlled trial, evaluating the safety, tolerability, and pharmacodynamic of continuous infusion of KL0011034 injection compared with propofol injectable emulsion for durations of 1 hour, 2 hours, and 3 hours, and evaluating the pharmacokinetic of the KL0011034 injection.

Read the detailed description

This study is a randomized, double-blind, active-controlled, continuous-infusion trial. It is planned to enroll 30 healthy subjects, who will be divided into three continuous-infusion groups (Groups 1 to 3), with 10 subjects per group. Block randomization will be used to assign subjects in a 4:1 ratio to either the test drug group or the active control group. In the test drug group, subjects will receive propofol injectable emulsion 2 mg/kg during the anesthesia induction phase, followed by KL0011034 injection during the anesthesia maintenance phase. In the active control group, subjects will receive propofol injectable emulsion 2 mg/kg during induction and propofol emulsion injection during maintenance. The maintenance durations for Groups 1, 2, and 3 are 1 hour (+5 min), 2 hours (+5 min), and 3 hours (+5 min), respectively. During the study, subjects will undergo assessments of safety, tolerability, and pharmacodynamics, and blood samples will be collected for pharmacokinetic analysis.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy
03

In context

Lead sponsor

Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

First submitted after Hunan Kelun Pharmaceutical Co., Ltd. became part of Sichuan Kelun Pharmaceutical Co.,Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form
  2. Health participants (Age: 18\~45 years);
  3. Body Weight: Male≥50.0kg, Female≥45.0kg; 19 ≤≤ 26.0kg/m2;
  4. There were no abnormalities in physical examination, vital signs, 12-lead , chest x-ray, abdominal B-ultrasound, laboratory tests;
  5. Agreed to use for 3 months post-dose.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or Drug ;
  2. Medical History;
  3. History of anesthesia accident, history of serious adverse reactions of anesthesia, or family history of anesthesia accidents, or to general anesthesia;
  4. Dyspnoea or suspected difficult airway, or predicting difficult endotracheal intubation;
  5. History of bronchial asthma, , sleep apnea syndrome;
  6. History of adrenal insufficiency or adrenal tumor or hereditary heme biosynthesis disorder or hereditary acute porphyria;
  7. History of any surgery within 3 months;
  8. History of any Medication within 14 days;
  9. History of any clinical study within 3 months;
  10. History of any vaccine within 1 month;
  11. History of any drug abuse;
  12. Needle sickness, Hematosickness;
  13. Massive blood loss (> 400 mL) in the past 3 months;
  14. Female volunteers are pregnant or lactating;
  15. History of unprotected sex within 2 weeks;
  16. Heavy smoker ( more than 5 cigarettes/day) within 3 months;
  17. History of alcohol abuse,or heavy alcohol intake (more than 14 units a week) within 6 months;
  18. Heavy caffeine intake;
  19. History of grapefruit, xanthine-rich foods intake within 48 hours;
  20. Positive alcohol test;
  21. Positive nicotine test;
  22. Positive drugs of abuse test result.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Low-dose group

    subjects will receive propofol injectable emulsion 2 mg/kg during the anesthesia induction phase, followed by KL0011034 injection or propofol injectable emulsion during the anesthesia maintenance phase. The maintenance durations for low-dose group is 1 hour (+5 min).

    Drug: KL0011034 injection · Drug: propofol injectable emulsion

  • Experimental
    Medium-dose group

    subjects will receive propofol injectable emulsion 2 mg/kg during the anesthesia induction phase, followed by KL0011034 injection or propofol injectable emulsion during the anesthesia maintenance phase. The maintenance durations for medium-dose group is 2 hours (+5 min).

    Drug: KL0011034 injection · Drug: propofol injectable emulsion

  • Experimental
    High-dose group

    subjects will receive propofol injectable emulsion 2 mg/kg during the anesthesia induction phase, followed by KL0011034 injection or propofol injectable emulsion during the anesthesia maintenance phase. The maintenance durations for high-dose group is 3 hours (+5 min).

    Drug: KL0011034 injection · Drug: propofol injectable emulsion

Interventions

06

What researchers measure

Primary outcomes

  1. Number of reported Adverse Events

    Safety and tolerability was assessed by the number of volunteers with adverse events.

    Time frame: 24 hours post-dose

Secondary outcomes

  1. PK parameter Cmax in plasma

    Maximum peak plasma concentration (Cmax) of KL0011034 and its metabolite

    Time frame: 24 hours post-dose

  2. PK parameter Tmax in plasma

    Time of Cmax (Tmax) of KL0011034 and its metabolite

    Time frame: 24 hours post-dose

  3. PK parameter AUC0-t in plasma

    Area under the concentration-time curve (AUC0-t) from time zero to time "t" of KL0011034 and its metabolite

    Time frame: 24 hours post-dose

  4. PK parameter AUC0-∞ in plasma

    AUC from time zero to infinity (AUC0-∞) of KL0011034 and its metabolite

    Time frame: 24 hours post-dose

  5. PK parameter t1/2 in plasma

    Terminal-phase elimination half-life (t1/2) of KL0011034 and its metabolite

    Time frame: 24 hours post-dose

  6. Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale

    MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.

    Time frame: Day 1

  7. Electroencephalogram bispectrality index (BIS) monitoring

    BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.

    Time frame: Day 1

  8. Modified Aldrete Scoring (Aldrete) Scale

    The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO₂. Ranging from 0 to 10, the higher the score, the better the quality of recovery.

    Time frame: Day 1

  9. Post-Anesthetic Discharge Scoring System

    PADSS assesses based on five dimensions: vital signs, activity status, nausea and vomiting, pain severity, and surgical bleeding. Each item is scored from 0 to 2, with a total score of 10, the higher the score, the better the quality of recovery. Discharge can be arranged when the score reaches 9.

    Time frame: Day 1

  10. The time of complete awakening

    The definition of complete awakening is that the MOAA/S score is 5 for three consecutive times. The time point when the first score among the three consecutive times is 5 is the time point of complete awakening.

    Time frame: Day 1

  11. Mini-Mental State Examination

    The quality of awakening was evaluated through the "orientation in the recovery period" and "memory" sections of the MMSE scale. The "orientation in the recovery period" assesses based on 10 questions, each question is scored from 0 to 1, with a total score of 10. The "memory" assesses based on 3 questions, including the repetition of 6 different things and performing 5 subtraction calculations, with a total score of 11. the higher the score, the better the quality of awakening.

    Time frame: Day 1

  12. Anesthesia satisfaction

    satisfaction of anesthesiologists and satisfaction of patients. The "satisfaction of patients" assesses based on 2 parts, with a total score of 150. the higher the score, the better the quality of recovery. Part A: How do you feeling in the past 24 hours ( including 10 questions, each question is scored from 0 to 10, with a total score of 100 ). Part B: Have you experienced following 5 situations in the past 24 hours ( each situation is scored from 0 to 10, with a total score of 50 ). The " satisfaction of anesthesiologists" assesses based on 2 dimensions: Maintaining hemodynamic stability during the maintenance period, and Awakening status (whether agitated, choking, or coughing). Each item is scored from 1 to 5, with a total score of 10, the higher the score, the better the quality of recovery.

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 18, 2026
StartEst.
Oct 13, 2026
Primary completionEst.
Nov 13, 2026
CompletionEst.
Nov 13, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07828470
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Oct 13, 2026 (estimated)
Primary completion
Nov 13, 2026 (estimated)
Completion
Nov 13, 2026 (estimated)
Last update
Sep 18, 2026

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KL0011034

Start the discussion